1. Introduction {#sec1}
===============

Childhood Pneumonia is an acute virus, bacterial, or fungal respiratory infection that affects the lungs \[[@B1]\]. The symptoms and signs of Childhood Pneumonia include cough, fever, rapid or difficult breathing, loss of appetite, and lower chest wall indrawing \[[@B2]\]. Auscultation reveals rales. However, severe Childhood Pneumonia is defined as cough or difficult breathing combined with lower chest wall indrawing \[[@B3]\]. Childhood Pneumonia has been identified as a mixed viral-bacterial infection in 23%--33% of cases \[[@B4]\]. Respiratory syncytial virus is the most common viral cause of children pneumonia, and *Streptococcus pneumoniae* is the most common cause of bacterial pneumonia in children \[[@B5]\]. Each year, pneumonia kills an estimated 1.4 million children \<5 years of age, accounting for 18% of all deaths worldwide \[[@B6]\]. Pneumonia is the most common reason for hospitalization in children \<2 years of age \[[@B7]\]. The cost of antibiotic treatment for all children with pneumonia in 42 of the poorest countries is estimated to be about US \$600 million per year. The estimated incidence rates are 0.29 and 0.05 episodes per child-year in low-income and high-income countries, respectively. Approximately 156 million new episodes occur each year, the majority in India (43 million), China (21 million), Pakistan (10 million), Bangladesh, Indonesia, and Nigeria (6 million each) \[[@B8]\].

Administering appropriate antibiotics at the early stage of pneumonia improves outcomes, particularly when the causative agent is bacterial \[[@B9]\]. However, antibiotic treatment of pneumonia in children remains mostly empirical because determining the etiologic pathogen is difficult in this age group \[[@B10]\]. According to the results of a questionnaire, the following agents have been used against Childhood Pneumonia: ampicillin, ampicillin/sulbactam, second/third generation cephalosporins, azithromycin, vancomycin, clindamycin, and linezolid. In subsequent analyses, we categorized ampicillin, ampicillin/sulbactam, and cephalosporins as beta-lactam antibiotics and vancomycin, clindamycin, and linezolid as antimethicillin-resistant*Staphylococcus aureus* antibiotics. Respondents were asked to select the duration of antibiotic therapy they would recommend for uncomplicated and parapneumonic empyema cases using the following categories: 3--5 days, 6-7 days, 8--10 days, 11--14 days, 15--21 days, and \>21 days \[[@B11]\]. Empirical antibiotic administration is relied upon in most instances to meet the public health goal of reducing child mortality due to pneumonia. This is necessary in view of the inability of most commonly available laboratory tests to identify causative pathogens. Empirical antibiotic administration is the main treatment for Childhood Pneumonia. Multiple antibiotics are prescribed for treating pneumonia, so it is important to know which work best for pneumonia in children \[[@B12]\].

Traditional Chinese Medicine (TCM) follows a particular theoretical and methodological approach to estimate the cause of a disease, leading to diagnosis and treatment \[[@B13]\]. Pneumonia is equivalent to the TCM cough category. Ma Xing Shi Gan Tang, San Ao Tang, Zhi Sou San, and other self-developed TCM prescriptions are Chinese medicinal formulas that have been used to treat Childhood Pneumonia for many years. In recent years, preparations of Chinese herbal medicines, such as Tanreqing injection, Chuanhuning injection, and Reduning injection have been used to treat Childhood Pneumonia in China. Chinese herbal medicine formulas function to clear heat, resolve phlegm, ventilate the lungs, dissipate phlegm, relieve cough, and reduce sputum. The function of Chinese herbal medicine preparations is to clear heat and remove toxicity. A study showed that the pharmacological action of Ma Xing Shi Gan Tang includes antiasthmatic, antitussive, and antiviral effects as well as bacteriostatic and immunoregulatory functions \[[@B14]\].

Although these formulae and other Chinese herbal medicine preparations have been used widely to treat Childhood Pneumonia in China, their effects and safety have not been reviewed systematically.

2. Methods {#sec2}
==========

2.1. Criteria for Considering Studies for this Paper {#sec2.1}
----------------------------------------------------

### 2.1.1. Types of Studies {#sec2.1.1}

Only randomized controlled trials (RCTs) were included.

### 2.1.2. Types of Participants {#sec2.1.2}

Studies that enrolled patients with pneumonia in children who had cough, fever \>37.5°C, raised respiratory rate, lower chest wall indrawing, rales, and changes on chest films were included. Patients with Childhood Pneumonia of either gender, any ethnic group, and ages of 1 month to 18 years were included. Studies were excluded if they included children suffering from other debilitating diseases.

### 2.1.3. Types of Interventions {#sec2.1.3}

There were Chinese medicinal herbs versus other drugs, formulas, and placebo alone; Chinese medicinal herbs plus basic therapy versus basic therapy. Antibiotics were one of the main basic therapies for Childhood Pneumonia. Prohibited or suspended Chinese herbal preparations were excluded.

### 2.1.4. Types of Outcome Measures {#sec2.1.4}

Primary outcomes included mortality and total effective rate (e.g., ratio of signs and symptoms improvement or recovery); secondary outcomes included time to clinical recovery (e.g., cough, fever, rales, and chest films), relapse rate, length of hospital stay, and adverse effects (e.g., nausea, diarrhea, vomiting, and gastrointestinal bleeding). TCM outcomes such as tongue coat, pulse condition, and economic index were included.

2.2. Search Methods for Identification Studies {#sec2.2}
----------------------------------------------

We searched for all relevant studies in the following electronic databases: PubMed (1966--July 2012), the Cochrane Central Register of Controlled Trials, EMBASE (1980--July 2012), the Chinese Biomedicine Database (CBM) (1976--July 2012), Chinese National Knowledge Internet (CNKI) (1979--July 2012), and Chinese Biomedical Journals (VIP) (1989--July 2012). All studies included were analyzed according to Cochrane Handbook criteria. The following search terms were used: (Chinese herbs OR Chinese traditional herbs OR Chinese medicinal herbs OR traditional Chinese herbs OR Chinese herbal medicines) AND (child pneumonia OR children pneumonia OR Childhood Pneumonia OR Pediatric Pneumonia OR Infantile Pneumonia). We conducted a manual search for the Journal of Guangzhou University of Traditional Chinese Medicine. We attempted to contact original authors to obtain the protocol for the studies.

2.3. Data Collection and Analysis {#sec2.3}
---------------------------------

### 2.3.1. Study Selection {#sec2.3.1}

Two review authors independently browsed the titles and abstracts of all articles identified by the literature search. The same review authors independently estimated whether the trials met the inclusion criteria. Disagreements were resolved by discussion or consultation with a third author. We assessed abstracts from the initial search independently to identify studies that met the inclusion criteria. We telephone-interviewed authors of Chinese language articles and emailed the original authors of English articles to identify the randomization procedure and other methodological questions to ensure that the included studies were RCTs. If the required information was not available or if the required information did not meet the inclusion criteria, the article was excluded.

### 2.3.2. Data Extraction and Management {#sec2.3.2}

We extracted data including methodological details and data from publications using a data extraction form. We extracted data on study characteristics, including methods, participants, interventions, and outcomes. There were no disagreements among the authors.

We extracted the formulation contents of the included studies, and the names of the herbs are provided in three languages (e.g., Chinese, Latin, and English) in [Table 1](#tab1){ref-type="table"}.

### 2.3.3. Assessment of Risk of Bias in Included Studies {#sec2.3.3}

The following items were independently assessed by our authors using the risk of bias assessment tool. (1) Was there adequate sequence generation (selection bias)? (2) Was allocation adequately concealed (selection bias)? (3) Was knowledge of the allocated interventions adequately prevented during the study (e.g., participants and personnel, outcome assessors) (detection bias)? (4) Were incomplete outcome data adequately addressed (attrition bias)? (5) Are reports of the study free of suggesting selective outcome reporting (reporting bias)? (6) Was the study apparently free of other problems that could put it at risk for bias?

### 2.3.4. Measures of Treatment Effect {#sec2.3.4}

Data analyses were performed using the Cochrane Collaboration\'s RevMan software, version 5.1.6. Results are expressed as risk ratios (RR) and 95% confidence intervals (CIs) for dichotomous outcomes (e.g., mortality, effective rate, adverse effects, and relapse rate) and as mean differences (MD) with 95% CIs for continuous outcomes (such as time to clinical recovery and length of hospital stay).

### 2.3.5. Assessment of Heterogeneity {#sec2.3.5}

Heterogeneity was analyzed using the chi-square test on *n* − 1 degrees of freedom, and an alpha of 0.05 was used for statistical significance with the *I* ^2^ test. *I* ^2^ values of 25, 50, and 75% corresponded to low, medium, and high levels of heterogeneity, respectively.

### 2.3.6. Data Synthesis {#sec2.3.6}

We used fixed-effects and random-effects models for the pooled data analysis. We performed a pooled analysis for the 14 studies.

### 2.3.7. Subgroup Analyses {#sec2.3.7}

Subgroup analyses were performed according to formula type and Chinese medicinal herb preparation type, using the same comparators (e.g., same types of antibiotics).

### 2.3.8. Sensitivity Analyses {#sec2.3.8}

Sensitivity analyses were conducted by excluding low-quality studies (based on descriptions of randomization, allocation concealment, blinded assessment of outcomes, and description/analyses of withdrawals and dropouts) and a comparison of the merger analysis results for the fixed- and random-effects models.

3. Results {#sec3}
==========

3.1. Search Results {#sec3.1}
-------------------

An initial search identified 2,502 potentially relevant articles. Of these, 15 were in the English database. A total of 891 articles were initially included after duplicate publications were removed and any obviously irrelevant were excluded; 800 articles were later excluded, because they did not meet the inclusion criteria. Of the 91 potentially eligible reports, 77 were excluded for further assessment because telephone interviews with the original authors revealed that they were not RCTs. Therefore, 14 studies (1,824 participants) were included in this paper. All 14 studies were published in Chinese ([Figure 1](#fig1){ref-type="fig"}).

3.2. Included Studies {#sec3.2}
---------------------

### 3.2.1. Participants {#sec3.2.1}

The ratio of male to female participants in the 14 studies was 879/615 \[[@B15]--[@B21], [@B23]--[@B28]\]. One study \[[@B22]\] did not report the number of males and females. In total, 1,824 children were included in the 14 studies, and all were from China \[[@B15]--[@B28]\]. The ages of the patients were 1 month--15 years. The average size of the trials was 130 participants (range 60--200 participants).

### 3.2.2. Inclusion Criteria {#sec3.2.2}

The diagnostic criteria for childhood pneumonia in all studies included fever \>37.5°C, chest recession, increased respiratory rate, cough, rales, or difficulty breathing combined with fast breathing and a change on chest films.

### 3.2.3. Intervention {#sec3.2.3}

Chinese medicinal herbs interventions were given as oral decoctions or intravenous infusions. The longest therapy duration was 3 weeks, and the shortest was 5 days. Follow-up duration was not mentioned by any of the authors. All 14 studies compared Chinese medicinal herbs plus basic therapy versus basic therapies.

### 3.2.4. Outcomes {#sec3.2.4}

All 14 studies \[[@B15]--[@B28]\] reported the total effective rate; seven studies \[[@B15], [@B17], [@B18], [@B21], [@B23], [@B25], [@B28]\] reported clinical recovery of cough, fever, rales, and chest films; four \[[@B16], [@B22], [@B24], [@B26]\] reported clinical recovery of cough, fever, and rales; one \[[@B27]\] reported clinical recovery of fever; three \[[@B15], [@B21], [@B22]\] reported adverse effects (e.g., nausea, vomiting, diarrhea, and gastrointestinal bleeding); and one \[[@B28]\] reported the length of hospital stay. The description of studies is detailed in the characteristics of included studies in [Table 2](#tab2){ref-type="table"}.

3.3. Risk of Bias in Included Studies {#sec3.3}
-------------------------------------

The methodological quality of each study\'s randomization sequence, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and potential threats are summarized in Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}.

### 3.3.1. Randomization and Allocation Concealment {#sec3.3.1}

Ten studies \[[@B15]--[@B20], [@B23], [@B25]--[@B27]\] reported using a random-number table, and four \[[@B21], [@B22], [@B24], [@B28]\] reported using a computer-generated random-number table. None of the trials used allocation concealment. Therefore, all studies had a high risk of selection bias.

### 3.3.2. Blinding {#sec3.3.2}

Ten studies \[[@B15]--[@B17], [@B20]--[@B24], [@B26], [@B27]\] used single blinding (outcome assessment was blinded). We interviewed the original authors by telephone to determine blinding because the blinding methods were not described. Thus, these studies had a low risk of performance bias and low detection bias. The other studies \[[@B18], [@B19], [@B25], [@B28]\] did not use blinding methods and had a high risk of performance bias or a strong detection bias.

### 3.3.3. Flow of Participants and Intention-to-Treat {#sec3.3.3}

None of the studies reported withdrawal, dropout, and/or loss during followup. The method of handling missing data regarding intention-to-treat or per-protocol analysis was not addressed.

### 3.3.4. Selective Reporting (Reporting Bias) {#sec3.3.4}

No detailed evidence of selective reporting was found in any of the 14 studies \[[@B15]--[@B28]\]. However, we believed there is a high risk of selective reporting bias because we were unable to compare the protocol with published studies.

### 3.3.5. Other Potential Sources of Bias {#sec3.3.5}

None of the 14 studies \[[@B15]--[@B28]\] did not describe patient compliance. The appropriateness of the statistical analyses used was assessed, and the methods of all studies were considered appropriate. Although we conducted comprehensive searches and tried to avoid bias, we could not exclude potential publication bias because all 14 studies were published in China.

4. Effects of Interventions {#sec4}
===========================

All studies compared Chinese medicinal herbs plus basic therapy to basic therapy alone. The Chinese medicinal herb treatments included the modified Ma Xing Shi Gan Tang formula, the San Ao Tang formula, the Zhi Sou San formula, a self-developed TCM prescription, Tanreqing injection, Reduning injection, and Chuanhuning injection. Antibiotics were one of main basic therapies for Childhood Pneumonia.

4.1. Total Effective Rate {#sec4.1}
-------------------------

A significant increase in total effective rate was observed with Chinese medicinal herbs plus basic therapy versus basic therapy ([Figure 4](#fig4){ref-type="fig"}, analysis 1.1; RR, 1.18; 95% CI, 1.11--1.26).

Subgroup five studies \[[@B15]--[@B19]\] compared the modified Ma Xing Shi Gan Tang formula plus azithromycin versus azithromycin and showed a significant increase in total effective rate ([Figure 4](#fig4){ref-type="fig"}; analysis 1.1.1 of analysis 1.1; RR, 1.18; 95% CI, 1.09--1.27).

Subgroup one study \[[@B20]\] compared the modified Ma Xing Shi Gan Tang formula plus ceftazidime versus ceftazidime and showed no difference in total effective rate ([Figure 4](#fig4){ref-type="fig"}; analysis 1.1.2 of analysis 1.1; RR, 1.11; 95% CI, 0.98--1.27).

Subgroup one study \[[@B21]\] compared the San Ao Tang formula plus azithromycin versus azithromycin and showed no difference in total effective rate ([Figure 4](#fig4){ref-type="fig"}; analysis 1.1.3 of analysis 1.1; RR, 0.99; 95% CI, 0.91--1.08).

Subgroup one study \[[@B22]\] compared the modified Zhi Sou San formula plus erythrocin versus erythrocin and showed a significant increase in total effective rate ([Figure 4](#fig4){ref-type="fig"}; analysis 1.1.4 of analysis 1.1; RR, 1.41; 95% CI, 1.24--1.61).

Subgroup one study \[[@B23]\] compared a self-developed TCM prescription plus erythrocin versus erythrocin and showed no difference in total effective rate ([Figure 4](#fig4){ref-type="fig"}; analysis 1.1.5 of analysis 1.1; RR, 1.13; 95% CI, 0.91--1.39).

Subgroup one study \[[@B24]\] compared Tanreqing injection plus antibiotics versus antibiotics and showed a significant difference in total effective rate ([Figure 4](#fig4){ref-type="fig"}; analysis 1.1.6 of analysis 1.1; RR, 1.28; 95% CI, 1.10--1.50).

Subgroup three studies \[[@B25]--[@B27]\] compared Reduning injection plus azithromycin versus azithromycin and showed a significant difference in total effective rate ([Figure 4](#fig4){ref-type="fig"}; analysis 1.1.7 of analysis 1.1; RR, 1.23; 95% CI, 1.04--1.46).

Subgroup one study \[[@B28]\] compared Chuanhuning injection plus piperacillin versus piperacillin and showed a significant difference in total effective rate ([Figure 4](#fig4){ref-type="fig"}; analysis 1.1.8 of analysis 1.1; RR, 1.14; 95% CI, 1.05--1.24).

4.2. Adverse Effects {#sec4.2}
--------------------

Three studies \[[@B15], [@B21], [@B22]\] compared Chinese medicinal herbs plus basic therapy versus basic therapy and showed no difference in adverse effects ([Figure 5](#fig5){ref-type="fig"}; analysis 1.2; RR, 0.39; 95% Cl, 0.09--1.72).

Subgroup one study \[[@B15]\] compared the modified Ma Xing Shi Gan Tang formula plus azithromycin versus azithromycin and showed no difference in adverse effects ([Figure 5](#fig5){ref-type="fig"}; analysis 1.2.1 of analysis 1.2; RR, 1.00; 95% CI, 0.34--2.90).

Subgroup one study \[[@B21]\] compared the San Ao Tang formula plus azithromycin versus azithromycin and showed no difference in adverse effects ([Figure 5](#fig5){ref-type="fig"}; analysis 1.2.2 of analysis 1.2; RR, 0.60; 95% CI, 0.15--2.41).

Subgroup one study \[[@B22]\] compared the modified Zhi Sou San formula plus erythrocin versus erythrocin and showed a significant decrease in adverse effects ([Figure 5](#fig5){ref-type="fig"}; analysis 1.2.3 of analysis 1.2; RR, 0.13; 95% CI, 0.07--0.23).

4.3. Time (Day) to Clinical Recovery Including Cough, Fever, Rales, and Chest Films {#sec4.3}
-----------------------------------------------------------------------------------

Studies investigating Chinese medicinal herbs plus basic therapy versus basic therapy showed a significant difference in cough ([Figure 6](#fig6){ref-type="fig"}; analysis 1.3; total MD, −2.18; 95% Cl, (−2.66)--(−1.71)), fever ([Figure 7](#fig7){ref-type="fig"}; analysis 1.4; total MD, −1.85; 95% Cl, (−2.29)--(−1.40)), rales ([Figure 8](#fig8){ref-type="fig"}; analysis 1.5; total MD, −1.53; 95% Cl, (−1.84)--(−1.23)), and chest films ([Figure 9](#fig9){ref-type="fig"}; analysis 1.6; total MD, −3.10; 95% Cl, (−4.11)--(−2.08)).

Subgroup two studies \[[@B16], [@B18]\] compared the modified Ma Xing Shi Gan Tang formula plus azithromycin versus azithromycin and showed a significant difference for cough ([Figure 6](#fig6){ref-type="fig"}; analysis 1.3.1 of analysis 1.3; MD, −2.55; 95% Cl, (−3.47)--(−1.63)), fever ([Figure 7](#fig7){ref-type="fig"}; analysis 1.4.1 of analysis 1.4; MD, −1.62; 95% Cl, (−2.49)--(−0.75)), and rales ([Figure 8](#fig8){ref-type="fig"}; analysis 1.5.1 of analysis 1.5; MD, −1.42; 95% Cl, (−2.40)--(−0.43)). Subgroup one study \[[@B18]\] compared the modified Ma Xing Shi Gan Tang formula plus azithromycin versus azithromycin and showed a significant difference on chest films ([Figure 9](#fig9){ref-type="fig"}; analysis 1.6.1 of analysis 1.6; MD, −1.77; 95% Cl, (−2.62)--(−0.92)).

Subgroup one study \[[@B21]\] compared the San Ao Tang formula plus azithromycin versus azithromycin and showed a significant difference in cough ([Figure 6](#fig6){ref-type="fig"}; analysis 1.3.2 of analysis 1.3; MD, −2.10; 95% Cl, (−2.94)--(−1.26)), fever ([Figure 7](#fig7){ref-type="fig"}; analysis 1.4.2 of analysis 1.4; MD, −2.50; 95% Cl, (−3.28)--(−1.72)), rales ([Figure 8](#fig8){ref-type="fig"}; analysis 1.5.2 of analysis 1.5; MD, −0.80; 95% Cl, (−1.42)--(−0.18)), and chest films ([Figure 9](#fig9){ref-type="fig"}; analysis 1.6.2 of analysis 1.6; MD, −5.00; 95% Cl, (−7.08)--(−2.92)).

Subgroup one study \[[@B22]\] compared the modified Zhi Sou San formula plus erythrocin versus erythrocin and showed a significant difference in cough ([Figure 6](#fig6){ref-type="fig"}; analysis 1.3.3 of analysis 1.3; MD, −1.70; 95% CI, (−2.03)--(−1.37)), fever ([Figure 7](#fig7){ref-type="fig"} analysis 1.4.3 of analysis 1.4; MD, −2.36; 95% Cl, (−2.55)--(−2.17)), and rales ([Figure 8](#fig8){ref-type="fig"} analysis 1.5.3 of analysis 1.5; MD, −2.02; 95% Cl, (−2.36)--(−1.68)).

Subgroup one study \[[@B23]\] compared a self-developed TCM prescription plus erythrocin versus erythrocin and showed a significant difference in cough ([Figure 6](#fig6){ref-type="fig"} analysis 1.3.4 of analysis 1.3; MD, 3.20; 95% CI, (−5.07)--(−1.33)), rales ([Figure 8](#fig8){ref-type="fig"} analysis 1.5.4 of analysis 1.5; MD, −2.11; 95% Cl, (−3.73)--(−0.49)), and chest films ([Figure 9](#fig9){ref-type="fig"} analysis 1.6.3 of analysis 1.6; MD, −3.06; 95% Cl, (−4.53)--(−1.59)), but no difference in fever ([Figure 7](#fig7){ref-type="fig"} analysis 1.4.4 of analysis 1.4; MD, −1.07; 95% Cl, −2.57--0.43).

Subgroup one study \[[@B24]\] compared Tanreqing injection plus antibiotics versus antibiotics and showed a significant difference in cough ([Figure 6](#fig6){ref-type="fig"} analysis 1.3.5 of analysis 1.3; MD, −1.20; 95% CI, (−1.37)--(−1.03)), fever ([Figure 7](#fig7){ref-type="fig"} analysis 1.4.5 of analysis 1.4; MD, −1.20; 95% Cl, (−1.69)--(−0.71)), and rales ([Figure 8](#fig8){ref-type="fig"} analysis 1.5.5 of analysis 1.5; MD, −1.44; 95% Cl, (−1.56)--(−1.32)).

Subgroup two studies \[[@B25], [@B26]\] compared Reduning injection plus azithromycin versus azithromycin and showed a significant difference in cough ([Figure 6](#fig6){ref-type="fig"} analysis 1.3.6 of analysis 1.3; MD, −2.48; 95% CI, (−3.22)--(−1.75)) and rales ([Figure 8](#fig8){ref-type="fig"} analysis 1.5.6 of analysis 1.5; MD, −2.00; 95% CI, (−2.94)--(−1.05)). Subgroup three studies \[[@B25]--[@B27]\] compared Reduning injection plus azithromycin versus azithromycin and showed a significant difference in fever ([Figure 7](#fig7){ref-type="fig"} analysis 1.4.6 of analysis 1.4; MD, −1.96; 95% CI, (−3.37)--(−0.55)). Subgroup one study \[[@B25]\] compared Reduning injection plus azithromycin versus azithromycin and showed a significant difference on chest films ([Figure 9](#fig9){ref-type="fig"} analysis 1.6.4 of analysis 1.6; MD, −2.90; 95% CI, (−5.26)--(−0.54)).

Subgroup one study \[[@B28]\] compared Chuanhuning injection plus piperacillin versus piperacillin and showed a significant difference in cough ([Figure 6](#fig6){ref-type="fig"} analysis 1.3.7 of analysis 1.3; MD, −2.47; 95% CI, (−2.89)--(−2.05)), fever ([Figure 7](#fig7){ref-type="fig"} analysis 1.4.7 of analysis 1.4; MD, −1.48; 95% CI, (−1.90)--(−1.06)), rales ([Figure 8](#fig8){ref-type="fig"} analysis 1.5.7 of analysis 1.5; MD, −1.70; 95% CI, (−2.18)--(−1.22)), and chest films ([Figure 9](#fig9){ref-type="fig"} analysis 1.6.5 of analysis 1.6; MD, −3.48; 95% CI, (−3.94)--(−3.02)).

4.4. Length of Hospital Stay {#sec4.4}
----------------------------

One study \[[@B28]\] compared Chuanhuning injection plus piperacillin versus piperacillin and showed a significant difference in length of hospital stay ([Figure 10](#fig10){ref-type="fig"} analysis 1.7; total MD, −3.00; 95% CI, (−3.52)--(−2.48)).

4.5. Other Outcomes {#sec4.5}
-------------------

Mortality, relapse rate, TCM outcomes (e.g., tongue coat and pulse condition), and economic index were not reported in any of the 14 studies.

5. GRADE Quality of Evidence {#sec5}
============================

The "GRADEprofiler" of the Cochrane Collaboration Network was used to classify the systematic review results. The quality of evidence was low to very low ([Table 3](#tab3){ref-type="table"}).

6. Discussion {#sec6}
=============

Based on the 14 \[[@B15]--[@B28]\] RCTs conducted in China, Chinese medicinal herbs increased total effective rates (e.g., ratio of signs and symptoms improvement or recovery) and improved clinical symptoms and signs (e.g., cough, fever, rales, and chest films). However, the evidence that Chinese medicinal herbs decreased adverse effects, mortality, or improved TCM outcomes (e.g., tongue coat and pulse condition) was insufficient. The quality of the evidence was weak due to selective bias, measurement bias, selective reporting bias, and imprecision. Therefore, evidence from the included studies was not enough to make any recommendations.

First, randomization was mentioned in all 14 studies. However, one study \[[@B25]\] described the randomization method in detail, whereas 13 did not \[[@B15]--[@B24], [@B26]--[@B28]\]. We interviewed the authors by telephone and determined that a random number table or a computer-generated random-number table was used to generate the allocation sequence. Second, none of the studies mentioned a blinding method, but we interviewed the authors by telephone and found that 10 studies \[[@B15]--[@B17], [@B20]--[@B24], [@B26], [@B27]\] used single blinding (i.e., the outcome assessment was blinded), and four \[[@B18], [@B19], [@B25], [@B28]\] did not. The lack of blinding participants, health-care providers, and assessors can introduce performance and detection bias. Third, none of the studies addressed the incomplete outcome data, such as missing data due to attrition or exclusion. The inadequate handling of missing data can compromise statistical analyses. Fourth, the majority of experimental Chinese herbal medicine interventions were prepared by the investigators without detailed information describing their underlying rationale for the formulation, dosage, or the manufacturing process, and the quality control processes for their tested interventions are unknown. Thus, independent validation of these findings is necessary.

This paper has several methodological limitations. First, although all data were collected from reports or from direct contact with the authors, many items on the "risk of bias" assessment tool could only be classified as "unclear." Second, different Chinese herbal medicine interventions were grouped together for analysis in some cases. The results might have been compromised by the heterogeneity within each Chinese herbal medicine intervention and the study design. Third, the concept of TCM syndrome was not considered when analyzing the data, as all studies only considered Childhood Pneumonia, not TCM symptoms. Therefore, the actual therapeutic effect might not have been fully captured.

Based on these reasons, the TCM RCTs should be conducted in accordance with the Consolidated Standards of Reporting Trials for Traditional Chinese Medicine \[[@B29]\] detailed report.

7. Conclusions {#sec7}
==============

Chinese herbal medicines may increase total effective rates, improve clinical symptoms and signs, and shorten the length of hospital stay for children with pneumonia. In a word, Chinese herbal medicines are effective for Childhood Pneumonia. However, there is insufficient evidence to confirm whether Chinese herbal medicines decrease adverse effects, mortality, and TCM outcomes (such as tongue coat and pulse condition). All results were supported by poor methodological quality studies. Thus, larger, multicenter, high methodological quality studies of Chinese herbal medicines for Childhood Pneumonia are needed. These studies should include patients with Childhood Pneumonia and interventions with Chinese herbal medicines. More data, particularly concerning adverse events, are necessary. Meanwhile, future studies should determine the most appropriate drug and dosage for Childhood Pneumonia. So, further trials would help to clarify the validity of the findings of this paper and could determine more clearly the role of Chinese herbal medicines in Childhood Pneumonia in comparison with other therapies. Consequently, the purpose is to guide our application in clinical.
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###### 

Contents of the formulations used and the three languages are included in the included studies.

  Study ID                         Herbs (composition) in three languages                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Method of administration
  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  Wang et al., 2009 \[[@B15]\]     Modified Ma Xing Shi Gan Tang: Mahuang (Herba Ephedrae/Ephedra Herb), Xingren (Armeniacae Amarum/Bitter Apricot Seed), Shigao (Gypsum Fibrosum/Gypsum), Gancao (Radix Glycyrrhizae/LiquoriceRoot), Yuxingcao (Herba Houttuyniae/Heartleaf Houttuynia Herb), lianqiao (Fructus Forsythiae/WeepingForsythiaecapsule), Chanyi (Periostracum Cicadae/Cicada Slough), and Niupangzi (Fructus Arctii/Great Burdock Achene)                                                                                                                                                                                                                                                            Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Zhao and Ji, 2009 \[[@B16]\]     Modified Ma Xing Shi Gan Tang: Mahuang (Herba Ephedrae/Ephedra Herb), Xingren (Armeniacae Amarum/Bitter Apricot Seed), Shigao (Gypsum Fibrosum/Gypsum), Gancao (Radix Glycyrrhizae/Liquorice Root), Yuxingcao (Herba Houttuyniae/Heartleaf Houttuynia Herb), and Huangqin (Radix Astragali Root)                                                                                                                                                                                                                                                                                                                                                                                Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Guo, 1999 \[[@B17]\]             Modified Ma Xing Shi Gan Tang: Mahuang (Herba Ephedrae/Ephedra Herb), Xingren (Armeniacae Amarum/Bitter Apricot Seed), Shigao (Gypsum Fibrosum/Gypsum), Gancao (Radix Glycyrrhizae/Liquorice Root), Yuxingcao (Herba Houttuyniae/Heartleaf Houttuynia Herb), and lianqiao (Fructus Forsythiae/WeepingForsythiaeCapsule)                                                                                                                                                                                                                                                                                                                                                         Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Zhang, 2012 \[[@B18]\]           Modified Ma Xing Shi Gan Tang: Mahuang (Herba Ephedrae/Ephedra Herb), Xingren (Armeniacae Amarum/Bitter Apricot Seed), Shigao (Gypsum Fibrosum/Gypsum), Gancao (Radix Glycyrrhizae/Liquorice Root), Yuxingcao (Herba Houttuyniae/Heartleaf Houttuynia Herb), and Huangqin (Radix Astragali Root)                                                                                                                                                                                                                                                                                                                                                                                Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  He, 2011 \[[@B19]\]              Modified Ma Xing Shi Gan Tang: Mahuang (Herba Ephedrae/Ephedra Herb), Xingren (Armeniacae Amarum/Bitter Apricot Seed), Jinhua (Flos Lonicerae/Honeysuckle Flower), Yinhua (Flos Lonicerae/Honeysuckle Flower), Shigao (Gypsum Fibrosum/Gypsum), Yuxingcao (Herba Houttuyniae/Heartleaf Houttuynia Herb), Banxia (Rhizome/Pinellia Tuberifera Tenora), and Gancao (Radix Glycyrrhizae/Liquorice Root)                                                                                                                                                                                                                                                                            Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  He et al., 2011 \[[@B20]\]       Modified Ma Xing Shi Gan Tang: Mahuang (Herba Ephedrae/Ephedra Herb), Xingren (Armeniacae Amarum/Bitter Apricot Seed), Shigao (Gypsum Fibrosum/Gypsum), Suzi (Fructus Perillae/PerillaFruit), Shangbaipi (Cortex Mori/White Mulberry Root Bark), Kuandonghua (Flos Farfarae/Common Coltsfoot Flower), Banxia (Rhizome/Pinellia Tuberifera Tenora), Tinglizi (Semen Lepidii/SemenDescurainiae Pepperweed Seed/Tansymustard), Yuxingcao (Herba Houttuyniae/Heartleaf Houttuynia Herb), and Gancao (Radix Glycyrrhizae/Liquorice Root)                                                                                                                                             Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Zhang, 2012 \[[@B21]\]           San Ao Tang: Mahuang (Herba Ephedrae/Ephedra Herb), Xingren (Armeniacae Amarum/Bitter Apricot Seed), and Gancao (Radix Glycyrrhizae/Liquorice Root)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Wang et al., 2009 \[[@B22]\]     Modified Zhi Sou San: Jiegeng (Radix Platycodi/Platycodon Root), Gancao (Radix Glycyrrhizae/Liquorice Root), Ziwan (Radix Asteris/Tatarian Aster Root), Chenpi (Pericarpium Citri Reticulatae/Tangerine Peel), Xingren (Armeniacae Amarum/Bitter Apricot Seed), Baiguo (Semen Gingko/Ginkgo Seed), Huangqi (Radix Astragali Root), Chaomaiya (Fructus Hordei Germina/Malt), Yunling (Poria/Indian Buead), and Baiqian (Rhizoma Cynanchi Stauntonii/Willowleaf Swallowwort Rhizome/Glaucescent)                                                                                                                                                                                  Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Lv et al., 2009 \[[@B23]\]       Self-Developed TCM Prescription: Mahuang (Herba Ephedrae/Ephedra Herb), Xingren (Armeniacae Amarum/Bitter Apricot Seed), Rengongniuhuang (Calculus Bovis/Bezoar), Baiqian (Rhizoma Cynanchi Stauntonii/Willowleaf Swallowwort Rhizome/Glaucescent), Shigao (Gypsum Fibrosum/Gypsum), Zhusha (Cinnabaris/Cinnabar), Chuanbeimu (Bulbus Fritillariae Unibracteatae/Unibract Fritillary Bulb), Huanglian (Rhizoma Coptidis/Golden Thread), Banxia (Rhizome/Pinellia Tuberifera Tenora), Dannanxing (Pinellia Pedatisecta/Arisaema with Bile), Shangbaipi (Cortex Mori/White Mulberry Root Bark), Huangqin (Radix Astragali Root), and Gancao (Radix Glycyrrhizae/Liquorice Root)   Oral administration
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Lei, 2010 \[[@B24]\]             Tanreqing injection: no information provided about Tanreqing composition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Intravenous injection
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Shi, 2009 \[[@B25]\]             Reduning injection: no information provided about Reduning composition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Intravenous injection
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Pan, 2011 \[[@B26]\]             Reduning injection: no information provided about Reduning composition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Intravenous injection
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Duan and Feng, 2011 \[[@B27]\]   Reduning injection: no information provided about Reduning composition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Intravenous injection
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Wei and Feng, 2003 \[[@B28]\]    Chuanhuning injection: no information provided about Chuanhuning composition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Intravenous injection

###### 

Characteristics of the included studies.

  Wang et al., 2009 \[[@B15]\]                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                       Randomized controlled trial (RCT): randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 3 weeks
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: we interviewed the author by telephone and learned that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that single blinding was used
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients
  Participants                                                                                                                                                                                         Country: China
  Number: 106 patients with childhood pneumonia                                                                                                                                                        
                                                                                                                                                                                                       54 boys (50.8%) and 52 girls (49.2%); age 3--14 years old; disease duration: not mentioned
  Interventions                                                                                                                                                                                        Treatment group: modified Ma Xing Shi Gan Tang formula plus basic therapy: Mahuang 6 g, Xingren 8 g, Shigao 15 g, Gancao 5 g, Yuxingcao 20 g, lianqiao 15 g, Chanyi 10 g, and Niupangzi 15 g boiled in 3 L water and decocted to 300 mL. Orally twice daily (bid) for 3 weeks
  Control group: basic therapy including intravenous infusion of azithromycin and azithromycin orally                                                                                                  
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate
  \(2\) Adverse effects (e.g., nausea, diarrhea, and vomit)                                                                                                                                            
  Notes                                                                                                                                                                                                \(1\) Duration of disease: not mentioned; (2) mortality: not mentioned; (3) relapse rate: not mentioned; (4) length of hospital stay: not mentioned; (5) clinical recovery (e.g., cough, fever, rales, and chest films): not mentioned; (6) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (7) economic index: not mentioned; (8) withdrawal rates: not specified; (9) source of funding: none
                                                                                                                                                                                                       
  Zhao and Ji, 2009 \[[@B16]\]                                                                                                                                                                         
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup was not mentioned
  Methods                                                                                                                                                                                              Study duration: not mentioned
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that single blinding was used
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients and outpatients
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 60 patients with childhood pneumonia
                                                                                                                                                                                                       Treatment group: 30 patients with childhood pneumonia: 16 boys (53%) and 14 girls (47%); age: 2 months--9 years (mean: 3.5 years); disease duration: 4.00 ± 1.55 years
                                                                                                                                                                                                       Control group: 30 patients with childhood pneumonia: 17 boys (56.6%) and 13 girls (43.4%); age: month --11 years (mean: 3.25 years); disease duration: 4.00 ± 1.75 years
  Interventions                                                                                                                                                                                        Treatment group: modified Ma Xing Shi Gan Tang formula plus basic therapy: Mahuang 6 g, Xingren 10 g, Shigao 20 g, Gancao 3 g, Yuxingcao 10 g, and Huangqin 10 g boiled in 3 L water and decocted to 300 mL. Orally twice daily (bid) for 3 weeks
  Control group: basic therapy including intravenous infusion of azithromycin and azithromycin orally                                                                                                  
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate
  \(2\) Clinical recovery (e.g., cough, fever, and rales)                                                                                                                                              
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) clinical recovery (e.g., chest films): not mentioned; (6) economic index: not mentioned; (7) withdrawal rates: not mentioned; (8) source of funding: none;(9)adverse effects (e.g., nausea, diarrhea, and vomiting): not mentioned
                                                                                                                                                                                                       
  Guo, 1999 \[[@B17]\]                                                                                                                                                                                 
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Not mentioned
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that single-blinding was used
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: not mentioned
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 170 patients with childhood pneumonia
                                                                                                                                                                                                       Treatment group: 86 patients with childhood pneumonia: 45 boys (52.3%) and 41 girls (48.7%); age: 2 months--12 years (mean: 3.8 years)
                                                                                                                                                                                                       Control group: 84 patients with childhood pneumonia: 44 boys (52.4%) and 40 girls (48.6%); age: 2 months--14 years (mean: 3.2 years)
  Interventions                                                                                                                                                                                        Treatment group: modified Ma Xing Shi Gan Tang formula plus basic therapy. Mahuang 1.5 g, Xingren 3 g, Shigao 10 g, Gancao 1.5 g, Yuxingcao 9 g, and lianqiao 3 g, boiled in 3 L water and decocted to 300 mL. Taken orally, three times daily (tid)
  Control group: basic therapy included penicillin, Xianfeng Meisu, and ribavirin. Intravenous infusion of azithromycin and azithromycin orally                                                        
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not specified; (7) source of funding: None; (8) time to measure outcomes: not mentioned; (9) 2. clinical recovery (e.g., cough, fever, rales, and chest films): not mentioned
                                                                                                                                                                                                       
  Zhang, 2012 \[[@B18]\]                                                                                                                                                                               
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 20 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. Telephone interview with author revealed that blinding was not used
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: not mentioned
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 200 patients with childhood pneumonia
                                                                                                                                                                                                       Treatment group: 100 patients with childhood pneumonia: 74 boys (74%) and 26 girls (47%); mean age: 6.28 years; disease duration: not mentioned
                                                                                                                                                                                                       Control group: 100 patients with childhood pneumonia: 68 boys (68%) and 32 girls (32%); age and duration of disease not mentioned
  Interventions                                                                                                                                                                                        Treatment group: modified Ma Xing Shi Gan Tang formula plus basic therapy. Mahuang 3 g, Xingren 4 g, Shigao 18 g, Gancao 3 g, Yuxingcao 9 g, and Huangqin 3 g boiled in 3 L water and decocted to 300 mL, taken orally twice daily (bid)
  Control group: basic therapy included intravenous infusion of azithromycin and azithromycin orally                                                                                                   
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate
  \(2\) Clinical recovery (e.g., cough, fever, rales, and chest films)                                                                                                                                 
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as the tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not mentioned; (7) source of funding: none; (8) time to measure outcomes: not mentioned; (9) adverse effects: not mentioned
                                                                                                                                                                                                       
  He, 2011 \[[@B19]\]                                                                                                                                                                                  
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 5--7 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that blinding was not used
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 100 patients with childhood pneumonia
                                                                                                                                                                                                       Treatment group: 50 patients with childhood pneumonia: 29 boys (54%) and 21 girls (42%); age: 9.6 months--12 years; disease duration: 4--8.5 days
                                                                                                                                                                                                       Control group: 50 patients with childhood pneumonia: 27 boys (54%) and 23 girls (46%); age: 10.8 months--13 years; disease duration: 5--8 days
  Interventions                                                                                                                                                                                        Treatment group: modified Ma Xing Shi Gan Tang formula plus basic therapy: Mahuang 3 g, Xingren 6 g, Jinhua 6 g, Yinhua 6 g, Shigao 12 g, Yuxingcao 9 g, Banxia 6 g, and Zhigancao 3 g boiled in 2 L water and decocted to 300 mL; taken orally twice daily (bid)
  Control group: intravenous infusion of azithromycin (10 mg/k · d)                                                                                                                                    
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not specified; (7) source of funding: none; (8) time to measure outcomes: not mentioned; (9) adverse effects: not mentioned; (10) clinical recovery (e.g., cough, fever, rales, and chest films): not mentioned
                                                                                                                                                                                                       
  He et al., 2011\[[@B20]\]                                                                                                                                                                            
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 7 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that blinding was used on outcome assessment
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 80 patients with childhood pneumonia
  Treatment group: 40 patients with childhood pneumonia: 22 boys (55%) and 18 girls (45%); mean age: 1.8 ± 1.10 years                                                                                  
                                                                                                                                                                                                       Control group: 40 patients with childhood pneumonia: 21 boys (52.5%) and 19 girls (47.5%); mean age: 1.75 ± 1.151 years
                                                                                                                                                                                                       Disease duration: 7.50 ± 0.50 days
  Interventions                                                                                                                                                                                        Treatment group: modified Ma Xing Shi Gan Tang formula plus basic therapy: Mahuang 3 g, Xingren 3 g, Shigao 9 g, Suzi 3 g, Shangbaipi 6 g, Kuandonghua 6 g, Banxia 6 g, Tinglizi 3 g, Yuxingcao 3 g, and Gancao 3 g boiled in 2 L water and decocted to 300 mL, taken orally twice daily (bid)
  Control group: basic therapy included supporting treatment and intravenous infusion of ceftazidime (0.1 g/kg · d)                                                                                    
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) adverse effects: not mentioned; (6) economic index: not mentioned; (7) withdrawal rates: not mentioned; (8) source of funding: none; (9) time to measure outcomes: not mentioned; (10) clinical recovery (e.g., cough, fever, rales, and chest films): not mentioned
                                                                                                                                                                                                       
  Zhang, 2012 \[[@B21]\]                                                                                                                                                                               
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 5--7 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a computer-generated random-number table was used
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that blinding was used on the outcome assessment
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 128 patients with childhood pneumonia
  Treatment group: 64 patients with childhood pneumonia in the treatment group                                                                                                                         
                                                                                                                                                                                                       Control group: 64 patients with childhood pneumonia in the control group
                                                                                                                                                                                                       In two groups, 79 boys (55%) and 49 girls (45%); age 1--14 years old; disease duration: 5--7 days
  Interventions                                                                                                                                                                                        Treatment group: San Ao Tang formula plus basic therapy; Mahuang 3 g, Xingren 12 g, Gancao 3 g boiled in 2 L water and decocted to 250 mL. Taken orally three times daily (tid)
  Control group: basic therapy included symptomatic therapy and orally azithromycin 10 mg/kg one time per day (qd)                                                                                     
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate; (2) clinical recovery (e.g., cough, fever, rales, and chest films); (3) adverse effects (e.g., nausea)
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not mentioned; (7) source of funding: none; (8) time to measure outcomes: not mentioned
                                                                                                                                                                                                       
  Wang et al., 2009 \[[@B22]\]                                                                                                                                                                         
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
                                                                                                                                                                                                       Study duration: 7 days
  Methods                                                                                                                                                                                              Parallel/crossover/factorial RCT: parallel
  Randomization method: a telephone interview with the author revealed that a computer-generated random-number table was used                                                                          
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that blinding was used on outcome assessment
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: patient source not mentioned
                                                                                                                                                                                                       Country: China
                                                                                                                                                                                                       Number: 200 patients with childhood pneumonia
  Participants                                                                                                                                                                                         Treatment group: 100 patients with childhood pneumonia in the treatment group
                                                                                                                                                                                                       Control group: 100 patients with childhood pneumonia in the control group
                                                                                                                                                                                                       Did not mention the number of boys and girls
                                                                                                                                                                                                       Disease duration: 5--7 days
  Interventions                                                                                                                                                                                        Treatment group: Zhi Sou San formula plus basic therapy: Jiegeng 6--9 g, Gancao 3--6 g, Ziwan 3--6 g, Chenpi 3--6 g, Xingren 3--6 g, Baiguo 3--6 g, Huangqi 3--6 g, Chaomaiya 3--6 g, Yunling 3--6 g, and Baiqian 3--6 g boiled in 2 L water. Taken orally three times daily (tid)
  Control group: basic therapy included symptomatic therapy and intravenous infusion of erythrocin (30 mg/kg · d)                                                                                      
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate; (2) clinical recovery (e.g., cough, fever, and rales); (3) adverse effects (e.g., nausea, vomiting, and gastrointestinal bleeding)
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not mentioned; (7) source of funding: none; (8) time to measure outcomes: not mentioned; (9) chest films: not mentioned
                                                                                                                                                                                                       
  Lv et al., 2009 \[[@B23]\]                                                                                                                                                                           
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup was not mentioned
  Methods                                                                                                                                                                                              Study duration: 10 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that blinding was used on the outcome assessment
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 60 patients with childhood pneumonia
                                                                                                                                                                                                       Treatment group: 30 patients with childhood pneumonia: 17 boys (56.7%) and 13 girls (43.3%); age: 8 months--13 years; disease duration: 7--18 days; mean: 14 days
                                                                                                                                                                                                       Control group: 30 patients with childhood pneumonia: 16 boys (53.3%) and 14 girls (46.7%); age: 7 months--12 years; disease duration: 7--18 days; mean: 13.5 days
  Interventions                                                                                                                                                                                        Treatment group: self-developed TCM prescription plus basic therapy: Mahuang 3 g, Xingren 3 g, Rengongniuhuang 3 g, Bingpian 2 g, Shengshigao 3 g, Zhusha 2 g, Chuanbeimu 2 g, Huanglian 2 g, Banxia 2 g, Dannanxing 2 g, Shangbaipi 2 g, Huangqin 2 g, and Gancao 2 g boiled in 3 L water and decocted to 300 mL. Taken orally three times daily (tid)
  Control group: basic therapy included symptomatic therapy and intravenous infusion of erythrocin (20 mg/kg bid)                                                                                      
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate; (2) clinical recovery (e.g., cough, fever, rales, and chest films)
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not mentioned; (7) source of funding: none; (8) time to measure outcomes: mentioned; (9) adverse effects: not mentioned
                                                                                                                                                                                                       
  Lei, 2010 \[[@B24]\]                                                                                                                                                                                 
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 7 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a computer-generated random-number table was used
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that blinding was used on the outcome assessment
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 160 patients with childhood pneumonia
                                                                                                                                                                                                       Treatment group: 80 patients with childhood pneumonia: 52 boys (65%) and 28 girls (35%); age: 6 months--12 years; disease duration: 2--7 days
                                                                                                                                                                                                       Control group: 80 patients with childhood pneumonia: 54 boys (67.5%) and 26 girls (32.5%); age: 5 months--13 years; disease duration: 1--6 days
  Interventions                                                                                                                                                                                        Treatment group: Tanreqing injection plus basic therapy: 30--50 mL/kg Tanreqing injection + 50--100 mL 10% GS intravenous infusion once daily (qd)
  Control group: basic therapy included anti-inflammatory, symptomatic therapy. Did not provide any detailed information about the anti-inflammatory, symptomatic therapy                              
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate; (2) clinical recovery (e.g., cough, fever, and rales).
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not mentioned; (7) source of funding: none; (8) time to measure outcomes: mentioned; (9) chest films: not mentioned; (10) adverse effects: not mentioned
                                                                                                                                                                                                       
  Shi, 2009 \[[@B25]\]                                                                                                                                                                                 
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 14 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that blinding was not used on study
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 80 patients with childhood pneumonia
                                                                                                                                                                                                       Treatment group: 40 patients with childhood pneumonia: 21 boys (52.5%) and 19 girls (47.5%)
                                                                                                                                                                                                       Control group: 40 patients with childhood pneumonia: 24 boys (60%) and 16 girls (40%); age: 5 months--13 years, in two groups; disease duration: 1--3 days
  Interventions                                                                                                                                                                                        Treatment group: Reduning injection plus basic therapy: 0.5--1.0 mL/kg · d Reduning injection + 250 mL 5% GS intravenous infusion once daily (qd)
  Control group: basic therapy included symptomatic therapy and intravenous infusion of 10 mg/kg · d azithromycin for 5 days, stop 3 days, then changed to oral 10 mg/kg · d azithromycin for 3 days   
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate; (2) clinical recovery (e.g., cough, fever, rales, and chest films)
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not mentioned; (7) source of funding: none; (8) time to measure outcomes: mentioned; (9) adverse effects: not mentioned
                                                                                                                                                                                                       
  Pan, 2011 \[[@B26]\]                                                                                                                                                                                 
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 7 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that the outcome assessment was blinding
                                                                                                                                                                                                       ITT: not mentioned.
                                                                                                                                                                                                       Setting: patient source not mentioned.
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 140 patients with childhood pneumonia
                                                                                                                                                                                                       Treatment group: 70 patients with childhood pneumonia: 42 boys (60%) and 28 girls (40%); age: 1--9 years old (mean: 5.1 ± 1.6 years); disease duration: 2--7 days
                                                                                                                                                                                                       Control group: 70 patients with childhood pneumonia: 36 boys (51.4%) and 34 girls (48.6%); age: 1--10 years old (mean: 5.1 ± 1.6 years); disease duration: 1--7 days
  Interventions                                                                                                                                                                                        Treatment group: Reduning injection plus basic therapy: 0.5--0.8 mL/kg Reduning injection + 100 mL 5% GS intravenous infusion once daily (qd)
  Control group: intravenous infusion of 10 mg/kg · d azithromycin + 5% GS once daily (qd)                                                                                                             
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate; (2) clinical recovery (e.g., cough, fever, and rales)
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) withdrawal rates: not mentioned; (7) source of funding: mentioned; (8) time to measure outcomes: not mentioned; (9) adverse effects: not mentioned; (10) chest films: not mentioned
                                                                                                                                                                                                       
  Duan and Feng, 2011 \[[@B27]\]                                                                                                                                                                       
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup was not mentioned
  Methods                                                                                                                                                                                              Study duration: 14 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a random number table was used to generate the random sequence
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that the outcome assessment was blinded
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: outpatients and inpatients
  Participants                                                                                                                                                                                         Country: China
  Number: 60 patients with childhood pneumonia                                                                                                                                                         
                                                                                                                                                                                                       In two groups: 35 boys (58.3%) and 25 girls (41.7%); age: 1--13 years; disease duration: 2--5 days
  Interventions                                                                                                                                                                                        Treatment group: Reduning injection plus basic therapy: 10--15 mL Reduning injection + 100 mL 5% GS intravenous infusion once daily (qd)
  Control group: intravenous infusion of 10 mg/kg · d azithromycin + 5% GS once daily (qd)                                                                                                             
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate; (2) clinical recovery (e.g., fever)
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) length of hospital stay: not mentioned; (4) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (5) economic index: not mentioned; (6) clinical recovery (e.g., cough, rales, and chest films): not mentioned; (7) withdrawal rates: not mentioned; (8) source of funding: none; (9) time to measure outcomes: not mentioned; (10) adverse effects: not mentioned
                                                                                                                                                                                                       
  Wei and Feng, 2003 \[[@B28]\]                                                                                                                                                                        
                                                                                                                                                                                                       
                                                                                                                                                                                                       RCT: randomization mentioned, but not described in detail
                                                                                                                                                                                                       Allocation concealment: not mentioned
                                                                                                                                                                                                       Followup: not mentioned
  Methods                                                                                                                                                                                              Study duration: 7--10 days
  Parallel/crossover/factorial RCT: parallel                                                                                                                                                           
                                                                                                                                                                                                       Randomization method: a telephone interview with the author revealed that a computer-generated random-number table was used
                                                                                                                                                                                                       Blinding: no detailed information on blindness was offered. A telephone interview with the author revealed that blinding was not used
                                                                                                                                                                                                       ITT: not mentioned
                                                                                                                                                                                                       Setting: inpatients
                                                                                                                                                                                                       Country: China
  Participants                                                                                                                                                                                         Number: 180 patients with childhood
  In two groups: 100 boys (55.6%) and 80 girls (44.4%); age: 2 months--5 years (mean: 2.3 years); disease duration: 1--7 days                                                                          
                                                                                                                                                                                                       Treatment group: 90 patients with childhood pneumonia; 52 boys (57.8%) and 38 girls (42.2%)
                                                                                                                                                                                                       Control group: 90 patients with childhood pneumonia; 48 boys (53.3%) and 42 girls (46.7%)
  Interventions                                                                                                                                                                                        Treatment group: Chuanhuning injection plus basic therapy: 10 mg/kg · d + 50--100 mL 10% GS or NS intravenous infusion once daily (qd)
  Control group: intravenous infusion of 100 mg/kg · d piperacillin twice daily (bid)                                                                                                                  
  Outcomes                                                                                                                                                                                             \(1\) Total effective rate; (2) length of hospital stay; (3) clinical recovery (e.g., cough, fever, rales, and chest films)
  Notes                                                                                                                                                                                                \(1\) Mortality: not mentioned; (2) relapse rate: not mentioned; (3) TCM outcomes, such as tongue coat and pulse condition: not mentioned; (4) economic index: not mentioned; (5) withdrawal rates: not mentioned; (6) source of funding: none; (7) time to measure outcomes: not mentioned; (8) adverse effects: not mentioned

###### 

Grade quality of evidence.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chinese medicinal herbs plus basic therapy versus basic therapy alone for childhood pneumonia                                                                                                                                                                                                             
  ----------------------------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------------- -------------------- -------------------------- ----------------------- -----------
                                                                                                  Illustrative comparative risks (95% CI)\*                                                                                                                                                                 

  Outcomes                                                                                        Assumed risk                                Corresponding risk                                                                    Relative effect \    Number of Participants \   Quality of evidence \   Comments
                                                                                                                                                                                                                                    (95% CI)             (studies)                  (grade)                 

                                                                                                  Control                                     Chinese medicinal herbs plus basic therapy versus basic therapy alone                                                                                          

                                                                                                                                                                                                                                                                                                            

                                                                                                  Study population                                                                                                                                                                                          

  Total effective rate                                                                            **779 per 1000**                            **920 per 1000** \                                                                                                                                             
                                                                                                                                              (865--982)                                                                                                                                                    

  Moderate                                                                                        **RR 1.18** \                               1720 \                                                                                ⊕⊕○○ \               Important                                          
                                                                                                  (1.11--1.26)                                (14 studies)                                                                          **Low** ^1,2^                                                           

                                                                                                  **800 per 1000**                            **944 per 1000** \                                                                                                                                             
                                                                                                                                              (888--1000)                                                                                                                                                   

                                                                                                                                                                                                                                                                                                            

                                                                                                  Study population                                                                                                                                                                                          

  Adverse effects                                                                                 **419 per 1000**                            **164 per 1000** \                                                                                                                                             
                                                                                                                                              (38--721)                                                                                                                                                     

  Moderate                                                                                        **RR 0.39** \                               434 \                                                                                 ⊕○○○ \               Important                                          
                                                                                                  (0.09--1.72)                                (3 studies)                                                                           **Very low** ^1,3^                                                      

                                                                                                  **113 per 1000**                            **44 per 1000** \                                                                                                                                              
                                                                                                                                              (10 to 194)                                                                                                                                                   

                                                                                                                                                                                                                                                                                                            

  Time (day) to improvement of cough                                                                                                          The mean time (days) to improvement in cough in the intervention groups was \                              1208 \                     ⊕⊕○○ \                  Important
                                                                                                                                              **2.18 lower** \                                                                                           (9 studies)                **Low** ^1,4^           
                                                                                                                                              (2.66 to 1.71 lower)                                                                                                                                          

                                                                                                                                                                                                                                                                                                            

  Time (day) to improvement of fever                                                                                                          The mean time (days) to improvement in fever in the intervention groups was \                              1262 \                     ⊕⊕○○ \                  Important
                                                                                                                                              **2.12 lower** \                                                                                           (10 studies)               **Low** ^1,2^           
                                                                                                                                              (2.25 to 1.98 lower)                                                                                                                                          

                                                                                                                                                                                                                                                                                                            

  Time (day) to improvement of rales                                                                                                          The mean time (days) to improvement in rales in the intervention groups was \                              1208 \                     ⊕⊕○○ \                  Important
                                                                                                                                              **1.53 lower** \                                                                                           (9 studies)                **Low** ^1,4^           
                                                                                                                                              (1.84 to 1.23 lower)                                                                                                                                          

                                                                                                                                                                                                                                                                                                            

  Time (day) to improvement in chest films                                                                                                    The mean time (days) to improvement in chest films in the intervention groups was \                        648 \                      ⊕⊕○○ \                  Important
                                                                                                                                              **3.1 lower** \                                                                                            (5 studies)                **Low** ^1,4^           
                                                                                                                                              (4.11 to 2.08 lower)                                                                                                                                          

                                                                                                                                                                                                                                                                                                            

  Length of hospital stay                                                                                                                     The mean length of hospital stay in the intervention groups was\                                           180 \                      ⊕○○○ \                  Important
                                                                                                                                              **3 lower** \                                                                                              (1 study)                  **Very low** ^1,5^      
                                                                                                                                              (3.52 to 2.48 lower)                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 \*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio.

Grade: working group grades of evidence.

**High quality:** further research is very unlikely to change our confidence in the estimate of effect. Handbook description: randomized controlled trial.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Cochrane Handbook description: relegation randomized controlled trial.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Cochrane Handbook description: two or more degradation factors of randomized controlled trials.

**Very low quality:** we are very uncertain about the estimate. Cochrane Handbook description: more than three degradation factors of randomized controlled trials.

Reduce the evidence quality factors: methodology defect, included in the research results of the inconsistency, indirect evidence, inexactness, and publication bias.

Increase the level of evidence factor: large effect quantity, confounding factors cannot change effect quantity, or the existing concentration-response relationship.

^1^There is a high risk of selection bias, performance bias, and detection bias.

^2^Some studies showed a significant difference, but some studies showed no significant difference.

^3^Few studies included.

^4^The protocol of the published studies could not be compared.

^5^Only one study included.

[^1]: Academic Editor: Zhao Xiang Bian
